These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Analysis of survival and treatment outcome of patients with primary diffuse large B cell lymphoma in reproductive system].
    Author: Yang P, Zhen JF, Pang M, Hu K, Zhao W, Dong F, Tian L, Ke XY, Jing HM.
    Journal: Zhonghua Yi Xue Za Zhi; 2018 May 29; 98(20):1593-1596. PubMed ID: 29886651.
    Abstract:
    Objective: To analyze clinical feature and treatment outcome of patients with primary diffuse large B cell lymphoma(DLBCL) in reproductive system. Methods: A total of 26 patients with DLBCL in reproductive system were retrospectively analyzed, and the clinical features, laboratory data were included in Kaplan-Meier and prognostic analysis. Results: In our center, the incidence of primary diffuse large B cell lymphoma in reproductive system was 3.5% in all DLBCL patients, and the median age was 62.0 years. Male are more common with unilateral testicular involvement, and 38.5% patients belong to Ⅲ and Ⅳstage while 84.6% patients belong to non-germinal center B cell-like subgroup. The overall response rate(ORR) for the whole group was 88.5%. The complete response rate was 76.9%. The 3, 5-year progression free survival rate was 70.5% and 62.7% , and the 3, 5-year overall survival rate was 83.5% and 69.6%, respectively. The most common recurrent sites were contralateral testis and central nervous system. Rituximab can improve the survival of patients and combined with contralateral irradiation can furtherly improve progression free survival of patients(P=0.047). Clinical stage, B symptom, IPI, the level of LDH, and CRP, age>60 years, and initial treatment outcome were predictive of overall survival. Conclusion: Primary diffuse large B cell lymphoma in reproductive system is a rare type of extranodal DLBCL which occurs in older men with aggressive features. The most common sites of recurrence were contralateral testis and central nervous system. Surgery, rituximab , radiotherapy and prophylactic intrathecal injection can improve the survival of patients and may be the first-line treatment. 目的： 探讨原发生殖系统弥漫大B细胞淋巴瘤(DLBCL)患者的临床特点、疗效分析。 方法： 回顾性分析26例原发生殖系统DLBCL患者的临床资料，对患者临床特征及实验室指标进行分析，同时进行生存和预后因素分析。 结果： 患者中位年龄62岁，男性多见，以单侧睾丸受累为主，Ⅲ、Ⅳ期患者占38.5%；84.6%患者为非生发中心来源(non－GCB)。治疗总有效率为88.5%，完全缓解率为76.9%，3和5年无进展生存率分别为70.5%和62.7%；3和5年总生存率分别83.5%和69.6%，对侧睾丸和中枢神经系统为最常见复发部位。美罗华治疗组优于未使用美罗华治疗组，但两者差异无统计学意义；联合对侧部位照射治疗能够提高患者无进展生存(P＝0.047)。对单因素预后分析显示临床分期、B症状(发热、盗汗或体重下降)、国际预后指数(IPI)评分、血清乳酸脱氢酶(LDH)水平、C－反应蛋白水平、发病年龄是否>60岁、近期疗效及是否为复发难治状态与预后相关。 结论： 原发生殖系统DLBCL是一种少见的结外DLBCL，好发于老年人，可表现为侵袭性临床特点，最常见复发部位为对侧睾丸和中枢神经系统。手术切除、美罗华联合治疗、对侧部位放疗及预防性鞘内注射能够提高患者生存，为一线治疗选择。.
    [Abstract] [Full Text] [Related] [New Search]